Molecule
Botulinum toxin type a is an acetylcholine release inhibitor indicated for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/ or procerus muscle activity in adult patients. MedsAcross supplies Botulinum toxin type a for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
DAXXIFY is an acetylcholine release inhibitor and neuromuscular-blocking agent indicated for: Temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/ or procerus muscle activity in adult patients. The treatment of cervical dystonia in adult patients.
Source: US FDA prescribing information
DAXXIFY blocks neuromuscular transmission at the neuromuscular junction by inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein necessary for the successful docking and release of acetylcholine vesicles within nerve endings. Recovery of neurotransmission occurs gradually as the neuromuscular junction recovers from SNAP-25 cleavage and as new nerve endings are formed.
Source: US FDA prescribing information
Glabellar Lines: the recommended dose is 0.1 mL (8 Units) by intramuscular injection into each of five sites, for a total dose of 40 Units. Cervical Dystonia: the recommended dose is 125 Units to 250 Units given intramuscularly as a divided dose among affected muscles.
Source: US FDA prescribing information
DAXXIFY is contraindicated in: patients with known hypersensitivity to any botulinum toxin preparation, DAXXIFY, or any of the components in the DAXXIFY formulation. the presence of infection at the proposed injection sites. Known hypersensitivity to any botulinum toxin preparation, DAXXIFY, or any of the components in the DAXXIFY formulation. Infection at the injection sites.
Source: US FDA prescribing information
Boxed warning (distant spread of toxin effect): The effects of all botulinum toxin products, including DAXXIFY, may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening, and there have been reports of death. The potency units of DAXXIFY are not interchangeable with other preparations of other botulinum toxin products. Spread of toxin effects, swallowing and breathing difficulties can lead to death. Seek immediate medical attention if respiratory, speech, or swallowing difficulties occur. Adverse event reports have been received involving the cardiovascular system with botulinum toxin products, some with fatal outcomes. Use caution when administering to patients with pre-existing cardiovascular disease.
Source: US FDA prescribing information
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Spread of Toxin Effect Hypersensitivity Reactions Cardiovascular System Adverse Reactions Increased Neuromuscular Compromise in Patients with Pre-Existing Neuromuscular Disorders Dysphagia and Breathing Difficulties Ophthalmic Adverse Reactions in Patients Treated for Glabellar Lines The most commonly observed adverse reactions are: Glabellar Lines (≥1%): headache (6%), eyelid ptosis (2%), and facial paresis (1%). Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (5%), muscular weakness (5%), and upper respiratory tract infection (5%).
Source: US FDA prescribing information
No formal drug interaction studies have been conducted with DAXXIFY. However, the potential for certain drugs to potentiate the effects of DAXXIFY warrants consideration given the potential risks involved and should be used with caution. Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY, co-administer only with caution and close observation.
Source: US FDA prescribing information
Unopened DAXXIFY vials should be stored at room temperature 20°C to 25°C (68°F to 77°F) or refrigerated at 2°C to 8° C (36°F to 46°F) in the original carton to protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
11 presentations of Botulinum toxin type a, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Xeomin 100 units powder for injectionIntramuscular Cold chain | Merz Pharmaceuticals | US FDA | Available on request |
| Xeomin 50 units powder for injectionIntramuscular Cold chain | Merz North | US FDA | Available on request |
| Botox 100 units powder for injectionIntradermal, intramuscular Cold chain | Allergan | US FDA | Available on request |
| Dysport 300 units powder for injectionIntramuscular Cold chain | Ipsen Biopharmaceuticals | US FDA | Available on request |
| BOTOX Cosmetic 100 units powder for injectionIntramuscular Cold chain | Allergan | US FDA | Available on request |
| Dysport 500 units powder for injectionIntramuscular Cold chain | Ipsen Biopharmaceuticals | US FDA | Available on request |
| Xeomin 200 units powder for injectionIntramuscular Cold chain | Merz Pharmaceuticals | US FDA | Available on request |
| Botox 200 units powder for injectionIntradermal, intramuscular Cold chain | Allergan | US FDA | Available on request |
| BOTOX Cosmetic 50 units powder for injectionIntramuscular Cold chain | Allergan | US FDA | Available on request |
| Daxxify 100 units/1.2 mL powder for injectionIntramuscular Cold chain | Revance Therapeutics | US FDA | Available on request |
| Jeuveau 100 units powderIntramuscular Cold chain | Evolus | US FDA | Available on request |
6 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | Not recorded | — |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Botulinum toxin type a in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 11 presentations of Botulinum toxin type a and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 6 brand names for Botulinum toxin type a, including Botox, BOTOX Cosmetic, Daxxify, Dysport, Jeuveau, Xeomin.
At least one listed presentation of Botulinum toxin type a must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.